News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
755,752 Results
Type
Article (53741)
Company Profile (451)
Press Release (701560)
Multimedia
Podcasts (91)
Webinars (13)
Section
Business (216944)
Career Advice (2857)
Deals (37240)
Drug Delivery (121)
Drug Development (86801)
Employer Resources (184)
FDA (17132)
Job Trends (15908)
News (368283)
Policy (35542)
Tag
Academia (2917)
Academic (1)
Accelerated approval (6)
Adcomms (27)
Allergies (93)
Alliances (53138)
ALS (99)
Alzheimer's disease (1486)
Antibody-drug conjugate (ADC) (149)
Approvals (17104)
Artificial intelligence (283)
Autoimmune disease (26)
Automation (16)
Bankruptcy (390)
Best Places to Work (12283)
BIOSECURE Act (20)
Biosimilars (115)
Biotechnology (340)
Bladder cancer (84)
Brain cancer (30)
Breast cancer (299)
Cancer (2393)
Cardiovascular disease (199)
Career advice (2396)
Career pathing (33)
CAR-T (164)
Cell therapy (459)
Cervical cancer (20)
Clinical research (70264)
Collaboration (897)
Compensation (537)
Complete response letters (28)
COVID-19 (2810)
CRISPR (48)
C-suite (263)
Cystic fibrosis (106)
Data (2254)
Decentralized trials (2)
Denatured (30)
Depression (55)
Diabetes (288)
Diagnostics (6725)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (130)
Drug pricing (120)
Drug shortages (28)
Duchenne muscular dystrophy (101)
Earnings (89282)
Editorial (43)
Employer branding (23)
Employer resources (157)
Events (120644)
Executive appointments (768)
FDA (18431)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (794)
Gene editing (116)
Generative AI (24)
Gene therapy (344)
GLP-1 (813)
Government (4882)
Grass and pollen (6)
Guidances (65)
Healthcare (20185)
Huntington's disease (25)
IgA nephropathy (31)
Immunology and inflammation (141)
Indications (30)
Infectious disease (2964)
Inflammatory bowel disease (150)
Inflation Reduction Act (11)
Influenza (55)
Intellectual property (100)
Interviews (554)
IPO (17104)
IRA (49)
Job creations (4078)
Job search strategy (1975)
Kidney cancer (11)
Labor market (38)
Layoffs (528)
Leadership (23)
Legal (8730)
Liver cancer (81)
Lung cancer (341)
Lymphoma (157)
Machine learning (7)
Management (62)
Manufacturing (327)
MASH (74)
Medical device (14055)
Medtech (14060)
Mergers & acquisitions (20672)
Metabolic disorders (758)
Multiple sclerosis (86)
NASH (23)
Neurodegenerative disease (110)
Neuropsychiatric disorders (34)
Neuroscience (2081)
NextGen: Class of 2025 (7238)
Non-profit (4897)
Now hiring (39)
Obesity (406)
Opinion (258)
Ovarian cancer (78)
Pain (97)
Pancreatic cancer (86)
Parkinson's disease (159)
Partnered (21)
Patents (246)
Patient recruitment (113)
Peanut (51)
People (62316)
Pharmaceutical (88)
Pharmacy benefit managers (19)
Phase I (21897)
Phase II (30839)
Phase III (22993)
Pipeline (1237)
Policy (161)
Postmarket research (2931)
Preclinical (9442)
Press Release (70)
Prostate cancer (112)
Psychedelics (38)
Radiopharmaceuticals (265)
Rare diseases (420)
Real estate (6424)
Recruiting (72)
Regulatory (24200)
Reports (47)
Research institute (2583)
Resumes & cover letters (453)
Rett syndrome (5)
RNA editing (5)
RSV (46)
Schizophrenia (80)
Series A (140)
Series B (91)
Service/supplier (13)
Sickle cell disease (58)
Special edition (17)
Spinal muscular atrophy (159)
Sponsored (32)
Startups (3908)
State (2)
Stomach cancer (16)
Supply chain (73)
Tariffs (43)
The Weekly (59)
Vaccines (772)
Venture capitalists (44)
Weight loss (284)
Women's health (38)
Worklife (19)
Date
Today (187)
Last 7 days (905)
Last 30 days (2762)
Last 365 days (34614)
2025 (11232)
2024 (37086)
2023 (41873)
2022 (53194)
2021 (57849)
2020 (56585)
2019 (49820)
2018 (37674)
2017 (34680)
2016 (34495)
2015 (40593)
2014 (34629)
2013 (29927)
2012 (31959)
2011 (32437)
2010 (30693)
Location
Africa (915)
Alabama (59)
Alaska (7)
Arizona (247)
Arkansas (14)
Asia (42740)
Australia (7750)
California (6324)
Canada (2048)
China (549)
Colorado (274)
Connecticut (291)
Delaware (153)
Europe (95558)
Florida (923)
Georgia (211)
Idaho (61)
Illinois (580)
India (27)
Indiana (317)
Iowa (12)
Japan (166)
Kansas (108)
Kentucky (26)
Louisiana (11)
Maine (62)
Maryland (940)
Massachusetts (4795)
Michigan (228)
Minnesota (409)
Mississippi (2)
Missouri (89)
Montana (30)
Nebraska (25)
Nevada (63)
New Hampshire (69)
New Jersey (1780)
New Mexico (31)
New York (1794)
North Carolina (1078)
North Dakota (8)
Northern California (2735)
Ohio (209)
Oklahoma (14)
Oregon (39)
Pennsylvania (1404)
Puerto Rico (13)
Rhode Island (36)
South America (1292)
South Carolina (22)
South Dakota (1)
Southern California (2359)
Tennessee (104)
Texas (933)
United States (24067)
Utah (187)
Virginia (154)
Washington D.C. (67)
Washington State (582)
West Virginia (3)
Wisconsin (57)
755,752 Results for "ebb therapeutics formerly known as cereve inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Press Releases
Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting
April 8, 2025
·
5 min read
Press Releases
Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025
April 1, 2025
·
7 min read
Press Releases
Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers
November 11, 2024
·
4 min read
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
January 21, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Sarah Sheikh Joins Cerevance’s Board of Directors
October 18, 2024
·
3 min read
Press Releases
New Data to Be Presented at Upcoming Congresses Showcase Cerevance’s Advanced Clinical Program in Parkinson’s Disease and Deep Pipeline for CNS-based Disorders
March 28, 2025
·
2 min read
Press Releases
Celltrion’s Remdantry™, previously known as Inflectra®, will be available in Canada as of April 1, 2025
March 27, 2025
·
3 min read
Genetown
Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters
Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, announced that the peer-reviewed journal, ACS Medicinal Chemistry Letters, has published the manuscript titled “Discovery of CVN293, a Brain Permeable KCNK13 Inhibitor Suitable for Clinical Assessment”.
April 22, 2024
·
3 min read
Genetown
Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024
Cerevance will deliver a poster presentation at the upcoming Federation of European Neuroscience Societies (FENS) Forum 2024, taking place in Vienna, Austria, from June 25 – 29, 2024.
June 18, 2024
·
2 min read
1 of 75,576
Next
